Proton and heavy ion therapy is becoming a hotspot in tumor radiotherapy due to its precise targeting of tumors and reduced damage to normal tissues. According to statistics from the Particle Therapy Co-Operative Group (PTCOG), over 300,000 patients worldwide have received this treatment. In China, multiple centers in Shanghai, Gansu, Shandong, and other regions are now operational, with the cumulative number of treated cases growing rapidly.
Proton and heavy ion therapy leverages the Bragg peak effect of charged particles in the body to deliver high-dose radiation to the tumor target while significantly reducing radiation exposure to surrounding critical organs. Clinical data show that for prostate cancer, lung cancer, liver cancer, skull base tumors, and pediatric tumors, local control rates and survival rates are comparable to or better than conventional radiotherapy, with a marked reduction in the incidence of severe side effects. For example, the Shanghai Proton and Heavy Ion Center reports a 5-year survival rate exceeding 90% for early-stage lung cancer patients and a biochemical control rate of 98% for prostate cancer patients.
Background and Significance
Although proton and heavy ion therapy started relatively late in China, it has developed rapidly. Currently, approximately 10 proton and heavy ion centers are in clinical use, covering provinces such as Shanghai, Guangdong, Shandong, and Gansu, with several more projects under construction. Breakthroughs in domestically produced equipment have gradually reduced treatment costs, but it remains a high-end medical resource. The widespread adoption of this technology is crucial for enhancing the precision of tumor treatment in China and meeting the diverse needs of patients.
Significance for International Patients
For international patients, receiving proton and heavy ion therapy in China offers unique value. Chinese centers employ internationally advanced rotating gantries and pencil beam scanning technology, with treatment planning systems aligned with those in Europe and the United States. Additionally, treatment costs are significantly lower than in Western countries, approximately one-third to one-half of the cost in the United States. For instance, a single course of treatment at the Shanghai Proton and Heavy Ion Center costs about 300,000 RMB, whereas comparable treatment in the U.S. can exceed $100,000. Furthermore, China's accumulated experience in head and neck tumors, pediatric tumors, and other areas provides international patients with more options.
How MedBridge Helps
MedBridge Shanghai, as a cross-border medical platform, offers international patients one-stop services from consultation to follow-up. We have established collaborations with proton and heavy ion centers in Shanghai, Guangdong, and other regions, and can assist patients with cost estimation, expert appointment scheduling, translation arrangements, and accommodation. Our medical team will evaluate whether proton and heavy ion therapy is suitable based on the patient's pathology and imaging data, and recommend the most appropriate medical institutions. During treatment, we provide full coordination to ensure patients receive care smoothly. For more details, feel free to contact us or browse our medical services.
Related reading: Overview of Partner Hospitals in Shanghai